Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nortriptyline + topiramate
- Development stage
- Phase 4
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of nortriptyline, a tricyclic antidepressant, and topiramate, an antiseizure medication, used primarily for migraine prevention. This combination is particularly effective in patients who have had incomplete relief with either agent alone. Nortriptyline works by inhibiting the reuptake of serotonin and norepinephrine, while topiramate influences GABA and glutamate receptors to act on cortical hyperexcitability.
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)iGluR (Ionotropic receptor 76b (Ir76b))GABRR (GABA-A receptor subunit rho)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)GABA-B (Gamma-aminobutyric acid receptor type B)
Beyond the preview
Go deeper on nortriptyline + topiramate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nortriptyline + topiramate.